Global Alpha 1 Antitrypsin Deficiency Treatment Market: Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025
"The Report Alpha 1
Antitrypsin Deficiency Treatment Market - Global Industry Analysis,
Size, Share, Growth, Trends, and Forecast 2017 - 2025 provides
information on pricing, market analysis, shares, forecast, and
company profiles for key industry participants. -
MarketResearchReports.biz"
About
Alpha
1 Antitrypsin Deficiency Treatment
Market
Alpha-1 Antitrypsin also referred
as AAT, is a type of protein belongs to the class protease inhibitor.
This protein is produced in the liver and is primarily functions to
protect the lungs and liver from the harmful effects of other protein
in the body. The AAT deficiency is genetic disorder that causes low
and defective production of AAT proteins in liver which results in
the accumulation of AAT in the liver and low amount of it in blood
stream. The presence of AAT deficiency can be diagnosed using blood
test, genetic tests and biopsy tests. Patients with severe AAT
deficiency get affected by liver cirrhosis, chronic obstructive
pulmonary diseases (COPD), and emphysema diseases. The diagnosis rate
for alpha-1 antitrypsin deficiency across the globe is one of the
crucial indicators of the alpha-1 antitrypsin deficiency treatment
market. The AAT deficiency disease can be treated using different
therapeutic methods such as augmentation therapy, bronchodilators,
corticosteroids, oxygen therapy and other treatment methods.
Get
Sample copy of this Report @
https://www.marketresearchreports.biz/sample/sample/1307134
Global Alpha-1 Antitrypsin
Deficiency Treatment Market: Trends and Opportunities
The
worldwide increase in the incidences and prevalence of respiratory
diseases is projected to be key driving factor for the global AAT
deficiency market during forecast period. According to the Forum of
International Respiratory Societies (FIRS), COPD affects more than
200 million people and is likely to be the fourth leading cause of
death in the world by 2030, while asthma affects about 235 million
people globally. AAT deficiency is most commonly observed in the
North America and European countries which is likely to drive the
market. The increasing awareness about AAT deficiency disorder in
developed countries, technological development in in the production
and purification of Alpha-1 Antitrypsin protein, and government
initiatives for increasing blood and plasma derived products would
boost the growth of global AAT deficiency treatment market. The AAT
deficiency is common, but under diagnosed condition in most of
countries. The slow diagnosis rates of AAT deficiency and high cost
of treatment is likely to hamper growth of global AAT deficiency
treatment market over forecast period. Alpha-1 antitrypsin deficiency
(A1AD) mostly occurs in the Caucasian population of European descent,
affecting approximately 100,000 Americans. However, most cases of
A1AD are undetected, making alpha-1 antitrypsin deficiency a highly
under-diagnosed disorder. Also the treatment of AAT deficiency may
lead to development of several chronic side effects such as
back/joint pain, chest pain, musculoskeletal pain, rhinorrhea,
sinusitis, fever, nausea, or shortness of breath, peripheral edema,
and urticarial. These side effects can sometimes force a patient to
discontinue the therapy as alpha-1 antitrypsin is a natural enzyme
inhibitor product.
Global Alpha-1 Antitrypsin
Deficiency Treatment Market: Geographical Segmentation
Geographically, the global AAT
deficiency treatment market has been segmented into five regions:
North America, Europe, Latin America, Asia Pacific, and Middle East &
Africa. The North America dominated the global AAT deficiency
treatment market in 2016 and is likely to lose its market share to
Europe by the end of 2025. Europe is projected to expand at highest
CAGR during forecast period and is likely to gain its market share by
the end of 2025. All the regions have been further segmented by
countries, product type, by material and End-user segments. The
competition matrix section included in the report is likely to assist
the existing players to increase their market shares and new
companies to establish their presence in the global AAT deficiency
treatment market. The report also profiles major players in the
market based on various attributes such as company overview,
financial overview, SWOT analysis, key business strategies, product
portfolio, and recent developments. Major companies competing in the
non-vascular stents market, and profiled in the report include
Grifols S.A., AstraZeneca, Teva Pharmaceutical Industries Ltd.,
Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., CSL Behring LLC,
Shire plc, Pfizer Inc., LFB Biomedicaments S.A., Kamada Ltd.
View Sample PDF @
https://www.marketresearchreports.biz/reports/1307134/alpha-antitrypsin-deficiency-treatment-market-research-reports.pdf
The
Global Alpha-1 Antitrypsin Deficiency Treatment Market has been
segmented as follows:
Global Alpha-1 Antitrypsin
Deficiency Treatment Market, by Treatment Type
Augmentation Therapy
Aralast
Prolastin
Zemaira/Respreeza
Glassia
Bronchodilator
Corticosteroids
Oxygen Therapy
Others
Global Alpha-1 Antitrypsin
Deficiency Treatment Market, by Route of Administration
Parenteral
Inhalations
Oral
Global Alpha-1 Antitrypsin
Deficiency Treatment Market, by End-User
Specialty Clinics
Hospitals
Pharmacies
Global Alpha-1 Antitrypsin
Deficiency Treatment Market, by Region
North America
Europe
Asia Pacific
Latin America
Middle East & Africa
Table of Content
Chapter 1. Preface
1.1. Report Scope and Market
Segmentation
1.2. Research Highlights
Chapter 2. Assumptions and
Research Methodology
2.1. Assumptions
2.2. Research Methodology
Chapter 3. Executive Summary:
3.1. Global Alpha-1 Antitrypsin
Deficiency Treatment: Market Snapshot
3.2. Market Share Analysis by
Region, 2016
Chapter 4. Market Overview
4.1. Market Overview
4.2. Global Alpha-1 Antitrypsin
Deficiency Treatment Market : Market Indicators
4.3. Global Alpha-1 Antitrypsin
Deficiency Treatment Market Size (US$ Mn) Forecast, 2015–2025
4.4. Global Alpha-1 Antitrypsin
Deficiency Treatment Market : Market Outlook
Send
An Enquiry Request @
https://www.marketresearchreports.biz/sample/enquiry/1307134
About us
MarketResearchReports.biz is the
most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
Comments
Post a Comment